BRPI0415020A - dissulfeto, sulfeto, sulfóxido e derivados de sulfona de açúcares cìclicos e usos dos mesmos - Google Patents

dissulfeto, sulfeto, sulfóxido e derivados de sulfona de açúcares cìclicos e usos dos mesmos

Info

Publication number
BRPI0415020A
BRPI0415020A BRPI0415020-1A BRPI0415020A BRPI0415020A BR PI0415020 A BRPI0415020 A BR PI0415020A BR PI0415020 A BRPI0415020 A BR PI0415020A BR PI0415020 A BRPI0415020 A BR PI0415020A
Authority
BR
Brazil
Prior art keywords
sulfoxide
disulfide
sulfide
cyclic sugars
sulfone derivatives
Prior art date
Application number
BRPI0415020-1A
Other languages
English (en)
Inventor
Moliner Jose Repoles
Perez-Rasilla Eduardo Salas
Coy Francisco Pubill
Original Assignee
Lacer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lacer Sa filed Critical Lacer Sa
Publication of BRPI0415020A publication Critical patent/BRPI0415020A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DISSULFETO, SULFETO, SULFóXIDO E DERIVADOS DE SULFONA DE AçúCARES CìCLICOS E USOS DOS MESMOS". Na presente invenção são divulgados novos derivados de mononitrato de dianidroexita, correspondentes à fórmula (I): e também os tautómeros, sais farmaceuticamente aceitáveis, pró-drogas e solvatos dos mesmos, assim como as composições farmacêuticas compreendendo esses compostos, alem do uso das mesmas.
BRPI0415020-1A 2003-10-03 2004-09-29 dissulfeto, sulfeto, sulfóxido e derivados de sulfona de açúcares cìclicos e usos dos mesmos BRPI0415020A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200302368A ES2258365B1 (es) 2003-10-03 2003-10-03 Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.
PCT/EP2004/010882 WO2005037842A1 (en) 2003-10-03 2004-09-29 Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0415020A true BRPI0415020A (pt) 2006-11-07

Family

ID=34451643

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415020-1A BRPI0415020A (pt) 2003-10-03 2004-09-29 dissulfeto, sulfeto, sulfóxido e derivados de sulfona de açúcares cìclicos e usos dos mesmos

Country Status (35)

Country Link
US (3) US7521571B2 (pt)
EP (1) EP1668017B1 (pt)
JP (2) JP4809769B2 (pt)
KR (1) KR101141683B1 (pt)
CN (1) CN1863805B (pt)
AP (1) AP1976A (pt)
AR (1) AR045962A1 (pt)
AT (1) ATE423781T1 (pt)
AU (1) AU2004281916B2 (pt)
BR (1) BRPI0415020A (pt)
CA (1) CA2540500C (pt)
DE (2) DE112004001860T5 (pt)
DK (1) DK1668017T3 (pt)
EA (1) EA008942B1 (pt)
EC (1) ECSP066542A (pt)
ES (2) ES2258365B1 (pt)
GB (1) GB2421241B (pt)
GE (1) GEP20084490B (pt)
GT (1) GT200400200A (pt)
HK (1) HK1092807A1 (pt)
HR (1) HRP20090152T3 (pt)
IL (1) IL174371A0 (pt)
IS (1) IS8436A (pt)
MX (1) MXPA06003610A (pt)
NO (1) NO20061872L (pt)
NZ (1) NZ546043A (pt)
PA (1) PA8614201A1 (pt)
PE (1) PE20050436A1 (pt)
PL (1) PL1668017T3 (pt)
PT (1) PT1668017E (pt)
RS (1) RS20060241A (pt)
SI (1) SI1668017T1 (pt)
UY (1) UY28547A1 (pt)
WO (1) WO2005037842A1 (pt)
ZA (1) ZA200603475B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.
EP1941876A1 (en) * 2006-12-28 2008-07-09 Lacer, S.A. Isosorbide mononitrate derivatives for the treatment of Inflammation and ocular hypertension
ES2332565B1 (es) * 2007-01-23 2010-10-21 Lacer, S.A. Uso de derivados de mononitrato de dianhidrohexita como agentes antiinflamatorios.
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
EP2117550A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678272A1 (en) * 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
IE20070934A1 (en) 2007-12-21 2009-06-24 Trinity College Dublin Efficient aspirin prodrugs
ES2393049T3 (es) * 2008-02-07 2012-12-18 Nicox S.A. Compuestos donantes de óxido nítrico
EP2149576A1 (en) * 2008-07-22 2010-02-03 Lacer, S.A. Isosorbide Nitrates having vasodilating activity
EP2149577B1 (en) 2008-07-22 2011-04-27 Lacer, S.A. New stereospecific method for the preparation of dioxa-bicyclooctane compounds
EP2177216A1 (en) * 2008-10-13 2010-04-21 Lacer, S.A. Use of dianhydrohexite mononitrate derivatives as healing agents
WO2010055138A1 (en) * 2008-11-14 2010-05-20 Lacer, S.A. New stereospecific method for the preparation of dioxa-bicyclooctane compounds
EP2199294A1 (en) * 2008-12-19 2010-06-23 Lacer, S.A. New stereospecific method for the preparation of dioxa bicyclooctane nitrate compounds
DK2515899T3 (en) * 2009-12-23 2016-08-15 Arca Biopharma Inc METHODS AND COMPOSITIONS FOR CARDIOVASCULAR DISEASES AND CONDITIONS
FR2977252B1 (fr) * 2011-06-30 2013-08-02 Seppic Sa Nouveaux esters de derives n-acyles d'acides amines et d'isosorbide, procede pour leur preparation, et utilisation en cosmetique et comme medicament.
JP6021938B2 (ja) 2011-12-16 2016-11-09 スリーエム イノベイティブ プロパティズ カンパニー メルカプト含有ビスアンヒドロヘキシトール誘導体及びその使用
US20160016969A1 (en) * 2013-03-05 2016-01-21 Archer Daniels Midland Company Isohexide monotriflates and process for synthesis thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU465217B2 (en) * 1971-04-29 1975-09-18 American Home Products Corporation Mononitrte esters of 1,4:3, 6-dianhydro-d-glucitol
US3886186A (en) 1971-04-29 1975-05-27 American Home Prod Mononitrate esters of 1,4:3,6-dianhydro-d-glucitol
DE3102947A1 (de) 1981-01-29 1982-09-02 Heinrich Mack Nachf., 7918 Illertissen Verfahren zur herstellung von isosorbid-5-nitrat
IT1204571B (it) * 1987-05-08 1989-03-10 Chiesi Farma Spa Esteri di 1,4:3,6-dianidrosorbitolo-2-mononitrato e 5-mononitrato,loro procedimento di preparazione e loro composizioni farmaceutiche
US4891373A (en) * 1988-11-23 1990-01-02 Pfizer Inc. Aminopropanol derivatives of 1,4:3,6-dianhydrohexitol nitrates, processes for their preparation and their use as medicaments
FR2680173A1 (fr) * 1991-08-07 1993-02-12 Hoechst Lab Nitrates organiques, leurs procedes de preparation et leur utilisation dans le traitement de maladies cardiovasculaires .
ES2125342T3 (es) * 1992-07-30 1999-03-01 Cal Int Ltd Esteres y combinaciones de un nitrato organico y de un salicilato.
DE4410997A1 (de) * 1994-03-30 1995-10-26 Isis Pharma Gmbh Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktionen
IL120531A (en) * 1997-03-26 2006-12-31 Yissum Res Dev Co Nitric oxide donors and pharmaceutical compositions containing them
ES2142773B1 (es) * 1998-10-07 2001-01-01 Lacer Sa Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida.
US20020013483A1 (en) 2000-07-13 2002-01-31 Consortium Fur Elektrochemische Industrie Gmbh Process for the preparation of dianhydrohexitol bisacylates
JP2004521083A (ja) * 2000-10-27 2004-07-15 ニトロメッド，インク． 酸化窒素不足によって特徴づけられる血管疾患の治療方法
UA63467A (en) 2003-04-22 2004-01-15 Pharmaceutical composition of organic nitrates, dosage form based on pharmaceutical composition of organic nitrates and method of manufacture
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.

Also Published As

Publication number Publication date
CN1863805B (zh) 2010-06-16
ES2258365A1 (es) 2006-08-16
JP2011012081A (ja) 2011-01-20
ES2258365B1 (es) 2007-12-01
GB0605574D0 (en) 2006-04-26
IL174371A0 (en) 2006-08-01
HRP20090152T3 (en) 2009-05-31
ES2322468T3 (es) 2009-06-22
ATE423781T1 (de) 2009-03-15
US20090169560A1 (en) 2009-07-02
DK1668017T3 (da) 2009-05-11
DE112004001860T5 (de) 2006-07-27
AP1976A (en) 2009-03-16
HK1092807A1 (en) 2007-02-16
EP1668017B1 (en) 2009-02-25
ECSP066542A (es) 2006-10-17
EA200600694A1 (ru) 2006-10-27
AR045962A1 (es) 2005-11-16
AU2004281916A1 (en) 2005-04-28
US7777058B2 (en) 2010-08-17
CA2540500C (en) 2012-08-28
NO20061872L (no) 2006-06-30
EA008942B1 (ru) 2007-10-26
GB2421241B (en) 2008-04-16
US7521571B2 (en) 2009-04-21
SI1668017T1 (sl) 2009-08-31
CA2540500A1 (en) 2005-04-28
KR20060066743A (ko) 2006-06-16
KR101141683B1 (ko) 2012-05-07
UY28547A1 (es) 2005-04-29
DE602004019666D1 (de) 2009-04-09
PE20050436A1 (es) 2005-06-23
EP1668017A1 (en) 2006-06-14
AU2004281916B2 (en) 2010-10-21
ZA200603475B (en) 2007-09-26
GB2421241A (en) 2006-06-21
IS8436A (is) 2006-05-03
GEP20084490B (en) 2008-09-25
GT200400200A (es) 2005-05-23
US20060235052A1 (en) 2006-10-19
JP4809769B2 (ja) 2011-11-09
US8541607B2 (en) 2013-09-24
PA8614201A1 (es) 2005-05-24
AP2006003605A0 (en) 2006-04-30
US20100196387A1 (en) 2010-08-05
WO2005037842A1 (en) 2005-04-28
NZ546043A (en) 2009-02-28
PT1668017E (pt) 2009-03-09
CN1863805A (zh) 2006-11-15
RS20060241A (en) 2008-06-05
PL1668017T3 (pl) 2009-07-31
MXPA06003610A (es) 2006-06-05
JP2007507451A (ja) 2007-03-29

Similar Documents

Publication Publication Date Title
BRPI0415020A (pt) dissulfeto, sulfeto, sulfóxido e derivados de sulfona de açúcares cìclicos e usos dos mesmos
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
BRPI0507085A (pt) derivados de sulfonamida, composição farmacêutica, usos, processos para preparação e combinação
ECSP055531A (es) "nuevos derivados de glicósido de tiofeno, metodos para la preparacion de los mismos, medicamentos que comprenden dichos compuestos, y su uso"
BR0210707A (pt) Formulações de olopatadina para administração tópica
DK0896533T3 (da) Pentafluorbenzensulfonamider og analoger
DOP2005000004A (es) "derivados sulfonamida para el tratamiento de enfermedades"
BR0314839A (pt) Compostos de alcina com efeito antagonista de mch e medicamentos que contêm esses compostos
DK0939627T3 (da) Pentaflourbenzensulfonamider og analoger
BR0214277A (pt) Solvatos de paclitaxel
BRPI0412851A (pt) benzamidazóis de n-metila-substituìdos
BR0208489A (pt) Derivados de n-(arilsulfonil) beta-aminoácidos, comportando um grupo aminoetilado substituìdo, o respectivo processo de preparação e as composições farmacêuticas que os contêm
UY28861A1 (es) Nuevas combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
BRPI0410660A (pt) derivados de 2-amino-piridina como agonistas de adrenoreceptor ß2
BRPI0408767A (pt) inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hiv
PT1261593E (pt) Derivados de 8,8a-di-hidro-ideno¬1,2-d|tiazole que possuem na posicao 2 um substituinte com uma estrutura de sulfona; procedimentos para a sua sintese e a sua utilizacao como farmacos
BR0314363A (pt) Indóis 2,4-substituìdos e seu uso como moduladores de 5-ht6
UY29394A1 (es) Derivados sustituidos de n-(5-(2-propilamino.1.hidroxietil)-2-hdroxifenil) metano sulfonamida, composiciones farmacéuticas que lo contienen y aplicaciónes.
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser
DK1809270T3 (da) 5,6,7-trihydroxyheptansyre og analoger til behandling af okulære sygdomme og sygdomme associeret med hyperproliferative og angiogeniske reaktioner
DE602004021385D1 (de) Indol-4 -sulfonamid-derivate, ihre herstellung und verwendung als 5-ht-6 modulatoren
BRPI0414644A (pt) composto, composições farmacêuticas, e, uso de um composto
BR0215189A (pt) Combinações de viscoelásticos para uso durante cirurgia
BR0012329A (pt) Derivados de benzofurano
AR035915A1 (es) Compuesto de {(2r)-2-[4-(4-{2-[(-metilsulfonil) amino]-etil} fenil) fenil) propil} [(metiletil) sulfonil) amina y sales farmaceuticamente aceptables del mismo; composiciones farmaceuticas que comprenden dicho compuesto; metodo para potenciar la funcion glutamato; para tratar estados depresivos; y ar

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 493/04, A61K 31/34, A61P 9/00

Ipc: C07D 493/04 (2011.01), A61K 31/34 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.